NII and Nottingham Scientists Discover Ark1 Enzyme Switch to Block Malaria Parasite Growth Scientists from NII Delhi and the University of Nottingham have identified the Ark1 enzyme as the cell division control switch in the malaria parasite. Blocking this target could halt rapid infection and bypass growing drug resistance. In a major scientific breakthrough against malaria, researchers from India and the United Kingdom have identified a key molecular switch that controls the reproduction of the malaria parasite. The joint study by scientists from the National Institute of Immunology (NII) in Delhi and the University of Nottingham revealed that an enzyme named Ark1 acts as the master regulator for cell division in Plasmodium vivax. By pinpointing this mechanism, scientists have opened the door for developing targeted therapies that can stop the parasite from multiplying inside the human body. A Ten-Thousand-Year Threat and the Current Global Toll Malaria remains one of humanity's oldest and deadliest infectious diseases, with evidence of its existence dating back over 10,000 years. Historically, India bore a crushing burden of the disease, suffering an estimated 83 lakh (8.3 million) annual deaths at its peak. While improved public health measures have drastically reduced mortality in India over the decades, malaria continues to pose a severe global health hazard, claiming approximately 8 lakh lives worldwide every year. The discovery of the parasite's genetic growth mechanism comes at a critical time as conventional treatments face rising biological resistance. How the Ark1 Enzyme Drives Rapid Parasite Multiplication The transmission of malaria relies on the Plasmodium vivax parasite, which initially resides inside mosquitoes. When an infected mosquito bites a human host, the parasite enters the bloodstream and initiates an extraordinarily rapid phase of cell division. Within mere seconds, the parasite multiplies into millions of new units, overwhelming the body's immune defenses. Researchers discovered that the Ark1 enzyme functions as the essential control switch driving this explosive cellular multiplication inside both humans and mosquitoes. Overcoming Sub-Micron Challenges with Ultra-Expansion Microscopy The research demonstrates that blocking the Ark1 enzyme can halt the growth and replication of Plasmodium vivax, functioning similarly to modern cholesterol-lowering drugs that block specific growth proteins. However, analyzing this interaction presented immense technological hurdles. The malaria parasite measures less than 1 micron, making it 50 to 100 times smaller than a human hair. When researchers genetically knocked out Ark1, tracking cellular changes inside such a tiny organism proved nearly impossible with standard lab equipment. To overcome this barrier, a research team led by Prof. Rita Tewari, a molecular parasitologist at the University of Nottingham's School of Life Sciences, utilized advanced imaging methods. "We used a new technique called Ultra-Expansion Microscopy, where the size of the cells is physically expanded by about five times from their normal state," stated Prof. Rita Tewari. This physical magnification allowed the research team to clearly observe the cellular impact of disabling the Ark1 enzyme. Overcoming Drug Resistance Through Kinase Targeting The identification of Ark1 provides a vital path forward as current antimalarial medications lose their effectiveness. Highlighting the urgency for novel treatments, Dr. Pushkar Sharma from NII noted, "Signs of resistance were first seen against chloroquine, and now resistance to artemisinin is also being observed." Dr. Pushkar Sharma explained that protein and lipid kinases serve as proven therapeutic targets across various complex diseases. The study confirms that Ark1 represents a viable target to prevent the proliferation of malaria parasites and counteract emerging drug resistance. What this means for you • Across India: The development of more effective antimalarial drugs will significantly strengthen national efforts toward complete malaria eradication. • Globally: It offers a breakthrough solution to overcome growing parasite resistance against traditional medications like chloroquine and artemisinin. Questions & Answers 1. What major discovery have scientists made regarding the malaria parasite? Researchers identified that the Ark1 enzyme acts as the main control switch driving rapid cell division in the Plasmodium vivax parasite. 2. How will targeting the Ark1 enzyme help treat malaria? Blocking the Ark1 enzyme halts the reproduction and expansion of the parasite inside the body, stopping the infection from progressing. 3. What technique allowed scientists to view the sub-micron parasite? Prof. Rita Tewari's team used Ultra-Expansion Microscopy, physically magnifying the parasite cells by roughly five times to observe internal structures. 4. Why is there an urgent need for new antimalarial drugs? Dr. Pushkar Sharma noted that parasites are developing resistance to existing drugs like chloroquine and artemisinin, making new therapeutic targets critical. https://trendkia.com/en/science/nii-aura-nottingham-ke-vaijnanikon-ki-bari-khoja-ark1-enjaima-ko-bloka-kara-maleriya-parajivi-ko-khatma-karane-ki-jagi-ummida-11661 TrendKia — Har trend, sabse pehle.